Practice Management News

The Trump Administration proposed a new rule last week to lower prices of prescription drugs and out-of-pocket costs by encouraging manufacturers to offer direct discounts to patients, according to a press release issued by HHS.

Adjusting the patient scheduling process improved patient punctuality as well as patient and provider satisfaction, according to findings recently published in Quality Management in Health Care.

More than 90% of physicians reported prior authorization requirements had a negative impact on patient clinical outcomes and that prior authorization procedures held up patient access to necessary care, according a new AMA survey.

Data from phase 1 of the nationwide Project in Osteopathic Medical Education and Empathy, or POMEE, have been used to develop the first and only national norm table of empathy scores for any first-year medical student enrolled in osteopathic colleges in the United States.

The Advisory Committee on Immunization Practices released its 2019 immunization schedule for adults aged 19 years and older, including new or revised recommendations for influenza, hepatitis A virus and hepatitis B virus vaccinations.

Patients treated with naloxone in the ED can be safely released following positive findings of six evaluation criteria, according to findings recently published in Academic Emergency Medicine.

Over the next few years, opioid misuse and overdose deaths are projected to substantially increase despite current efforts to prevent abuse, according to findings published in JAMA Network Open.

Although pediatric medical organizations, including the American Academy of Pediatrics, have demanded congressional legislation to ensure that new parents receive 12 weeks of paid family leave — based on evidence of health benefits to the child — it appears that physicians are not following their own advice on the matter.

In 2018, after President Donald Trump publicly condemned the pharmaceutical industry for skyrocketing prescription drug prices, several of the largest drug manufacturers — including Merck, Novartis, Pfizer and Roche — announced a series of temporary price freezes to their brand-name medications.

Requiring pharmaceutical companies to disclose prices in direct-to-consumer pharmaceutical advertising could potentially reduce interest in high-priced drugs, according to findings presented in JAMA Internal Medicine.